Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of psilocybin for treatment-resistant depression
2019-003984-24Phase 2Completed
- Sponsor
- Central Institute of Mental Health
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of psilocybin in treatment-resistant depression (TRD) and major depressive disorder (MDD) (3 arms), sponsored by Central Institute of Mental Health. Primary endpoint: Treatment responder rate at 6 weeks. Started Sep 2020; status: completed.
02
Drugs
psilocybin
03
Conditions
treatment-resistant depression (TRD)major depressive disorder (MDD)
Beyond the preview
Go deeper on 2019-003984-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003984-24.